Prot #54767414MMY3010: An Open-Label Treatment Use Protocol for Daratumumab in Subjects with Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor and an Immunomodulatory Agent) or are Double Refractory to

Project: Research project

Project Details

StatusFinished
Effective start/end date10/23/15 → 10/23/18

Funding

  • Janssen Research & Development, LLC (Prot #54767414MMY3010)